The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Open accessAbstract
NK cells have therapeutic potential for a wide variety of human malignancies. However, because NK cells expand poorly in vitro, have limited life spans in vivo, and represent a small fraction of peripheral white blood cells, obtaining sufficient cell numbers is the major obstacle for NK-cell immunotherapy. Genetically-engineered artificial antigen-presenting cells (aAPCs) expressing membrane-bound IL-15 (mbIL15) have been used to propagate clinical-grade NK cells for human trials of adoptive immunotherapy, but ex vivo proliferation has been limited by telomere shortening. We developed K562-based aAPCs with membrane-bound IL-21 (mbIL21) and assessed their ability to support human NK-cell proliferation. In contrast to mbIL15, mbIL21-expressing aAPCs promoted log-phase NK cell expansion without evidence of senescence for up to 6 weeks of culture. By day 21, parallel expansion of NK cells from 22 donors demonstrated a mean 47,967-fold expansion (median 31,747) when co-cultured with aAPCs expressing mbIL21 compared to 825-fold expansion (median 325) with mbIL15. Despite the significant increase in proliferation, mbIL21-expanded NK cells also showed a significant increase in telomere length compared to freshly obtained NK cells, suggesting a possible mechanism for their sustained proliferation. NK cells expanded with mbIL21 were similar in phenotype and cytotoxicity to those expanded with mbIL15, with retained donor KIR repertoires and high expression of NCRs, CD16, and NKG2D, but had superior cytokine secretion. The mbIL21-expanded NK cells showed increased transcription of the activating receptor CD160, but otherwise had remarkably similar mRNA expression profiles of the 96 genes assessed. mbIL21-expanded NK cells had significant cytotoxicity against all tumor cell lines tested, retained responsiveness to inhibitory KIR ligands, and demonstrated enhanced killing via antibody-dependent cell cytotoxicity. Thus, aAPCs expressing mbIL21 promote improved proliferation of human NK cells with longer telomeres and less senescence, supporting their clinical use in propagating NK cells for adoptive immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Natural Killer Cells: Their Roles in Defenses Against Disease
Herberman, R. B., & Ortaldo, J. R. (1981) · Science · doi:10.1126/science.7025208 · Cited by 1,336
Parrish-Novak, J., Dillon, S. R., Nelson, A., Hammond, A., Sprecher, C., Gross, J. A., Johnston, J., Madden, K., Xu, W., West, J., et al. (2000) · Nature · doi:10.1038/35040504 · Cited by 1,224
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Romagnani, C., Juelke, K., Falco, M., Morandi, B., D’Agostino, A., Costa, R., Ratto, G., Forte, G., Carrega, P., Lui, G., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.4947 · Cited by 494
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., & Caligiuri, M. A. (2002) · Blood · doi:10.1182/blood-2002-02-0350 · Cited by 491
IL-21 Limits NK Cell Responses and Promotes Antigen-Specific T Cell Activation
Kasaian, M. T., Whitters, M. J., Carter, L. L., Lowe, L. D., Jussif, J. M., Deng, B., Johnson, K. A., Witek, J. S., Senices, M., Konz, R. F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00295-9 · Cited by 481
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46
Walzer, T., Bléry, M., Chaix, J., Fuseri, N., Chasson, L., Robbins, S. H., Jaeger, S., André, P., Gauthier, L., Daniel, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609692104 · Cited by 476
Parkhurst, M. R., Riley, J. P., Dudley, M. E., & Rosenberg, S. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1347 · Cited by 475
Maus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., & June, C. H. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-143 · Cited by 454
Flow cytometry and FISH to measure the average length of telomeres (flow FISH)
Baerlocher, G. M., Vulto, I., de Jong, G., & Lansdorp, P. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.263 · Cited by 449
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R., Carson, L. F., Argenta, P. A., Jonson, A. L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2010.515582 · Cited by 436
IL-21 in Synergy with IL-15 or IL-18 Enhances IFN-γ Production in Human NK and T Cells
Strengell, M., Matikainen, S., Sirén, J., Lehtonen, A., Foster, D., Julkunen, I., & Sareneva, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.11.5464 · Cited by 394
The molecular basis of IL-21–mediated proliferation
Zeng, R., Spolski, R., Casas, E., Zhu, W., Levy, D. E., & Leonard, W. J. (2007) · Blood · doi:10.1182/blood-2006-10-054973 · Cited by 316
Berg, M., Lundqvist, A., McCoy, P., Samsel, L., Fan, Y., Tawab, A., & Childs, R. (2009) · Cytotherapy · doi:10.1080/14653240902807034 · Cited by 304
Tran, K. Q., Zhou, J., Durflinger, K. H., Langhan, M. M., Shelton, T. E., Wunderlich, J. R., Robbins, P. F., Rosenberg, S. A., & Dudley, M. E. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31818403d5 · Cited by 287
Iliopoulou, E. G., Kountourakis, P., Karamouzis, M. V., Doufexis, D., Ardavanis, A., Baxevanis, C. N., Rigatos, G., Papamichail, M., & Perez, S. A. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0904-3 · Cited by 277
Suhoski, M. M., Golovina, T. N., Aqui, N. A., Tai, V. C., Varela-Rohena, A., Milone, M. C., Carroll, R. G., Riley, J. L., & June, C. H. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300134 · Cited by 266
Lichtenfels, R., Biddison, W. E., Schulz, H., Vogt, A. B., & Martin, R. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90110-4 · Cited by 263
Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System
Singh, H., Manuri, P. R., Olivares, S., Dara, N., Dawson, M. J., Huls, H., Hackett, P. B., Kohn, D. B., Shpall, E. J., Champlin, R. E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5600 · Cited by 246
Self-citationCytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Cho, D., Shook, D. R., Shimasaki, N., Chang, Y.-H., Fujisaki, H., & Campana, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0735 · Cited by 234
Natural killer cell‐based immunotherapy in cancer: current insights and future prospects
Sutlu, T., & Alici, E. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02121.x · Cited by 200
Singh, H., Figliola, M. J., Dawson, M. J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3843 · Cited by 199
Self-citationVitale, M., Chiesa, M. D., Carlomagno, S., Romagnani, C., Thiel, A., Moretta, L., & Moretta, A. (2004) · European Journal of Immunology · doi:10.1002/eji.200425100 · Cited by 197
Alici, E., Sutlu, T., Björkstrand, B., Gilljam, M., Stellan, B., Nahi, H., Quezada, H. C., Gahrton, G., Ljunggren, H.-G., & Dilber, M. S. (2008) · Blood · doi:10.1182/blood-2007-09-110312 · Cited by 197
Shi, J., Tricot, G., Szmania, S., Rosen, N., Garg, T. K., Malaviarachchi, P. A., Moreno, A., DuPont, B., Hsu, K. C., Baxter‐Lowe, L. A., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07340.x · Cited by 194
Spanholtz, J., Tordoir, M., Eissens, D., Preijers, F., van der Meer, A., Joosten, I., Schaap, N., de Witte, T. M., & Dolstra, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009221 · Cited by 188
de Rham, C., Ferrari-Lacraz, S., Jendly, S., Schneiter, G., Dayer, J.-M., & Villard, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2336 · Cited by 184
PERUSSIA, B., Ramoni, C., Anegón, I., Cuturi, M. C., Faust, J. S., & Trinchieri, G. (1987) · PubMed · Cited by 181
Allogeneic natural killer cells for refractory lymphoma
Bachanova, V., Burns, L. J., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lindgren, B. R., Cooley, S., Weisdorf, D., & Miller, J. S. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0896-z · Cited by 177
Sivori, S., Cantoni, C., Parolini, S., Marcenaro, E., Conte, R., Moretta, L., & Moretta, A. (2003) · European Journal of Immunology · doi:10.1002/eji.200324533 · Cited by 173
Tokuyama, H., Hagi, T., Mattarollo, S. R., Morley, J. S., Wang, Q., So, H.-F., Moriyasu, F., Nieda, M., & Nicol, A. J. (2008) · International Journal of Cancer · doi:10.1002/ijc.23365 · Cited by 169
Interleukin‐21 activates human natural killer cells and modulates their surface receptor expression
Skak, K., Frederiksen, K. S., & Lundsgaard, D. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02730.x · Cited by 165
Alloreactive killer cells: hindrance and help for haematopoietic transplants
Parham, P., & McQueen, K. (2003) · Nature reviews. Immunology · doi:10.1038/nri999 · Cited by 162
Clausen, J., Vergeiner, B., Enk, M., Petzer, A. L., Gastl, G., & Gunsilius, E. (2003) · Immunobiology · doi:10.1078/0171-2985-00219 · Cited by 160
Bouteiller, P. P. L., Barakonyi, A., Giustiniani, J., Lenfant, F., Marie‐Cardine, A., Aguerre‐Girr, M., Rabot, M., Hilgert, I., Mami‐Chouaib, F., Tabiasco, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012681099 · Cited by 146
A new method for in vitro expansion of cytotoxic human CD3−CD56+ natural killer cells
Carlens, S., Gilljam, M., Chambers, B. J., ASCHAN, J., Guvén, H., Ljunggren, H., Christensson, B., & Dilber, M. S. (2001) · Human Immunology · doi:10.1016/s0198-8859(01)00313-5 · Cited by 144
IL-21 Down-Regulates NKG2D/DAP10 Expression on Human NK and CD8+ T Cells1
Burgess, S., Marusina, A., Pathmanathan, I., Borrego, F., & Coligan, J. (2006) · Journal of Immunology · doi:10.4049/jimmunol.176.3.1490 · Cited by 140
Koehl, U., Sörensen, J., Esser, R., Zimmermann, S. Y., Grüttner, H. P., Tonn, T., Seidl, C., Seifried, E., Klingebiel, T. E., & Schwabe, D. (2004) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2004.08.013 · Cited by 139
Sütlü, T., Stellan, B., Gilljam, M., Quezada, H. C., Nahi, H., Gahrton, G., & Alici, E. (2010) · Cytotherapy · doi:10.3109/14653249.2010.504770 · Cited by 137
Reim, F., Dombrowski, Y., Ritter, C., Buttmann, M., Häusler, S. F., Ossadnik, M., Krockenberger, M., Beier, D., Beier, C. P., Dietl, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0834 · Cited by 134
The Interactions of Multiple Cytokines Control NK Cell Maturation
Brady, J., Carotta, S., Thong, R. P. L., Chan, C. J., Hayakawa, Y., Smyth, M. J., & Nutt, S. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903354 · Cited by 130 · cited 2×
“The discovery of IL-21 was linked to its role in proliferation and maturation of NK cells [49], but subsequent studies have been widely disparate, identifying it as both activating and suppressive [50,51,52].”
BackgroundResultIL-21 Enhances Tumor Rejection through a NKG2D-Dependent Mechanism
Takaki, R., Hayakawa, Y., Nelson, A., Sivakumar, P. V., Hughes, S. D., Smyth, M. J., & Lanier, L. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2167 · Cited by 130
Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets
Roda, J. M., Parihar, R., Lehman, A., Mani, A., Tridandapani, S., & Carson, W. E. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.120 · Cited by 129
Konnikova, L., Simeone, M., Kruger, M. M., Kotecki, M., & Cochran, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0924 · Cited by 124
Barakonyi, A., Rabot, M., Marie‐Cardine, A., Aguerre‐Girr, M., Polgár, B., Schiavon, V., Bensussan, A., & Bouteiller, P. P. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5349 · Cited by 120
Ex vivo expansion of natural killer cells for clinical applications
Klingemann, H.-G., & Martinson, J. (2004) · Cytotherapy · doi:10.1080/14653240310004548 · Cited by 117
EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS FOR CANCER IMMUNOTHERAPY
Cho, D., & Campana, D. (2009) · The Korean Journal of Laboratory Medicine · doi:10.3343/kjlm.2009.29.2.89 · Cited by 113
Replicative potential of human natural killer cells
Fujisaki, H., Kakuda, H., Imai, C., Mullighan, C. G., & Campana, D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07667.x · Cited by 103
Clemenceau, B., Congy‐Jolivet, N., Gallot, G., Vivien, R., Gaschet, J., Thibault, G., & Vié, H. (2006) · Blood · doi:10.1182/blood-2005-09-3775 · Cited by 100
Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy
Jung, S. T., Kang, T. H., Kelton, W., & Georgiou, G. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.03.002 · Cited by 99
Tomala, J., Chmelova, H., Mrkvan, T., Řı́hová, B., & Kovář, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900284 · Cited by 98
Buddingh, E. P., Schilham, M. W., Ruslan, S. E. N., Berghuis, D., Szuhai, K., Suurmond, J., Taminiau, A. H. M., Gelderblom, H. A. J., Egeler, R. M., Serra, M., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0965-3 · Cited by 97
Umbilical Cord Mesenchymal Stem Cells Increase Expansion of Cord Blood Natural Killer Cells
Boissel, L., Tuncer, H. H., Betancur, M., Wolfberg, A., & Klingemann, H. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.06.016 · Cited by 97
Siegler, U., Meyer‐Monard, S., Jörger, S., Stern, M., Tichelli, A., Gratwohl, A. A., Wodnar‐Filipowicz, A., & Kalberer, C. P. (2010) · Cytotherapy · doi:10.3109/14653241003786155 · Cited by 94
Interleukin‐21 differentially affects human natural killer cell subsets
Wendt, K., Wilk, E., Buyny, S., et al. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02675.x · Cited by 83
Portevin, D., Poupot, M., Rolland, O., Turrin, C., Fournié, J., Majoral, J., Caminade, A., & Poupot, R. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-82 · Cited by 81
Interleukin-21: A new modulator of immunity, infection, and cancer
BRANDT, K., Singh, P. B., Bulfone‐Paus, S., & RUCKERT, R. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.04.003 · Cited by 80
Cytokine requirements for the growth and development of mouse NK cells in vitro
Toomey, J. A., Gays, F., Foster, D., & Brooks, C. G. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303097 · Cited by 77
Nitta, E., Yamashita, M., Hosokawa, K., Xian, M., Takubo, K., Arai, F., Nakada, S., & Suda, T. (2011) · Blood · doi:10.1182/blood-2010-08-297390 · Cited by 72
Decot, V., Voillard, L., Latger‐Cannard, V., Aïssi-Rothé, L., Perrier, P., Stoltz, J., & Bensoussan, D. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.02.006 · Cited by 70
Giustiniani, J., Bensussan, A., & Marie‐Cardine, A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.63 · Cited by 66
The immunobiology of natural killer cells and bone marrow allograft rejection.
Barão, I., & Murphy, W. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2003.09.002 · Cited by 65
Giustiniani, J., Marie‐Cardine, A., & Bensussan, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1293 · Cited by 63
High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma
Akamatsu, N., Yamada, Y., Hasegawa, H., Makabe, K., Asano, R., Kumagai, I., Murata, K., Imaizumi, Y., Tsukasaki, K., Tsuruda, K., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.06.001 · Cited by 61
Gong, W., Xiao, W., Hu, M., Weng, X., Li, Q., Pan, X., & Ming-chun, J. (2010) · Tissue Antigens · doi:10.1111/j.1399-0039.2010.01535.x · Cited by 56
Cholujová, D., Jakubı́ková, J., Kubeš, M., Arendacká, B., Sapák, M., Ihnatko, R., & Sedlák, J. (2008) · Immunobiology · doi:10.1016/j.imbio.2008.02.006 · Cited by 52
Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells
Zhang, H., Cui, Y., Voong, N., Sabatino, M., Stroncek, D. F., Morisot, S., Civin, C. I., Wayne, A. S., Levine, B. L., & Mackall, C. L. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31820d2a21 · Cited by 49
Meyer‐Monard, S., Passweg, J. R., Siegler, U., Kalberer, C. P., Koehl, U., Rovó, A., Halter, J. P., Stern, M., Heim, D. A., Gratwohl, J. R. A., et al. (2008) · Transfusion · doi:10.1111/j.1537-2995.2008.01969.x · Cited by 49
DAVIES, J. K., Singh, H., Huls, H. M., Yuk, D., Lee, D. A., Kebriaei, P., Champlin, R. E., Nadler, L. M., Guinan, E. C., & Cooper, L. J. N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3845 · Cited by 45
Self-citationEffect of IL-21 on NK cells derived from different umbilical cord blood populations
Perez, S. A., Mahaira, L. G., Sotiropoulou, P. A., Gritzapis, A. D., Iliopoulou, E. G., Niarchos, D. K., Cacoullos, N. T., Kavalakis, Y., Antsaklis, A. J., Sotiriadou, N. N., et al. (2005) · International Immunology · doi:10.1093/intimm/dxh348 · Cited by 42
Wu, Z., & Xu, Y. (2010) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq012 · Cited by 39
Numbenjapon, T., Serrano, L. M., Singh, H., Kowolik, C. M., Olivares, S., Gonzalez, N., Chang, W. C., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Leukemia · doi:10.1038/sj.leu.2404329 · Cited by 29
Self-citationCl??menceau, B., Gallot, G., Vivien, R., Gaschet, J., Campone, M., & Vi??, H. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175686.13368.5c · Cited by 25
Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients
Pittari, G., Fregni, G., Roguet, L., Garcia, A., Vataire, A.-L., Wittnebel, S., Amsellem, S., Chouaïb, S., Bourhis, J.-H., & Caignard, A. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.265 · Cited by 24
Endogenous IL-21 Restricts CD8+ T Cell Expansion and Is not Required for Tumor Immunity
Søndergaard, H., Coquet, J. M., Uldrich, A. P., McLaughlin, N. M., Godfrey, D. I., Sivakumar, P. V., Skak, K., & Smyth, M. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902697 · Cited by 22
Killer Ig-Like Receptor Ligand Mismatch Directs NK Cell Expansion In Vitro
Rose, M., Brööks, A. G., Stewart, L. A., Nguyen, T. H. O., & Schwarer, A. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803323 · Cited by 20
Ansén, S., Butler, M. O., Berezovskaya, A., Murray, A. P., Stevenson, K. E., Nadler, L. M., & Hirano, N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1146 · Cited by 20
Bonanno, G., Mariotti, A., Procoli, A., Corallo, M., Scambia, G., Pierelli, L., & Rutella, S. (2009) · BMC Immunology · doi:10.1186/1471-2172-10-46 · Cited by 13
Clausen, J., Enk, M., Vergeiner, B., Eisendle, K., Petzer, A. L., Gastl, G. A., & Gunsilius, E. (2004) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.06.009 · Cited by 9
Lü, H., Zhu, A.-Y., Chen, Y., Tang, J., & Li, B. (2011) · Human Immunology · doi:10.1016/j.humimm.2011.03.022 · Cited by 6
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
Self-citationCAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
“[88] The method has also been adapted to large-scale GMP and recently successfully used to generate large numbers of NK cells or CAR-NK cells for phase 1 and 2 clinical trials.”
Method
Metadata
- Authors
- Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., Champlin, R. E., Cooper, L. J. N., & Lee, D. A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-01-18
- Volume
- 7
- Issue
- 1
- Pages
- e30264
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2091675007
- Cited by
- 683
- References
- 86
- FWCI
- 13.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.